Fixed-Combination Hypertension Drugs Get Clearer Regulatory Pathway, But Will Pharma Follow?
Executive Summary
Significant effects are expected to be observed on both systolic and diastolic blood pressures, US FDA final guidance says in lone substantive change from January draft aimed at streamlining development for multi-drug combinations of previously approved products; with only five such products in the clinical pipeline according to Biomedtracker data, there appears to be little big pharma interest in this space.
You may also be interested in...
Hypertension Drug Development To Be Streamlined Under US FDA Guidance
Sponsors will need fewer dosage comparisons in factorial studies of fixed-dose hypertension combination products under the draft guidance.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.